Current Edition


Novartis suspends production of two radiopharmaceutical drugs over quality concerns

Dive Brief: Novartis has suspended production of two cancer drugs at plants in Italy and New Jersey due to “potential quality issues” it identified in …

Continue Reading →

Novartis wins FDA OK for radiopharmaceutical drug, cashing in on Endocyte deal

Dive Brief: Novartis has won Food and Drug Administration approval to sell a radiopharmaceutical designed to treat a form of advanced prostate cancer in a …

Continue Reading →